| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/05/2004 | US20040024034 For modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus |
| 02/05/2004 | US20040024030 Such as 4-chloro-5-(2-phenyl-thiazol-5-yl)-2H-pyrazole-3-carboxylic acid ethyl amide; for inhibiting topoisomerases; treating bacterial infections in mammals |
| 02/05/2004 | US20040024029 Thiazole and oxazole derivatives |
| 02/05/2004 | US20040024025 Compositions and methods for inducing cell death |
| 02/05/2004 | US20040024023 1-Heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands |
| 02/05/2004 | US20040024014 Such as 2-(nitrooxy)ethyl-2-(((3-methyl-4-(2,2,2-trifluoro-ethoxy)-2 -pyridyl)methyl)sulfinyl)benzimidazolecarboxylate; kits; for treating gastrointestinal disorders/ulcers |
| 02/05/2004 | US20040024000 Dihydropyrimidine derivatives as cysteine protease inhibitors |
| 02/05/2004 | US20040023998 2-(5-amino-6-oxo-2-phenyl-1,6-dihydro-1-pyrimidyl)-N-(1-(2-(5-t -butyl-1,3,4-oxadiazolyl)carbonyl)-2-(R,S)-methylpropyl) acetamide; elastase inhibitors |
| 02/05/2004 | US20040023997 5-amino-pyrazolo-(4, 3-e)-1,2,4-triazolo(1,5-c)pyrimidine derivatives; treating parkinson's disease and other central nervous system disorders |
| 02/05/2004 | US20040023996 Methods and compositions utilizing quinazolinones |
| 02/05/2004 | US20040023995 Pyridopyrimidine compounds and their uses |
| 02/05/2004 | US20040023992 Antiinflammatory agents |
| 02/05/2004 | US20040023991 Use of pyrazolo[4,3-d]pyrimidines |
| 02/05/2004 | US20040023989 Pyrazolo(4,3-c)piperidine and pyrazolo(4,3-d)pyrimidine derivatives |
| 02/05/2004 | US20040023988 Novel compounds |
| 02/05/2004 | US20040023974 Pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula I inhibit PTP-1B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present |
| 02/05/2004 | US20040023973 Novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. |
| 02/05/2004 | US20040023972 Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS |
| 02/05/2004 | US20040023970 Method for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I |
| 02/05/2004 | US20040023963 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| 02/05/2004 | US20040023954 Hypotensive drugs Bimatoprost, Latanaprost, Unoprostone, Travoprost and prostaglandin H2 1-ethanolamide or of structurally closely related analogs, are pro-drugs which hydrolyze under physiological conditions to provide |
| 02/05/2004 | US20040023945 Cyclic amp-specific phosphodiesterase inhibitors |
| 02/05/2004 | US20040023937 Anti-cancer formulation |
| 02/05/2004 | US20040023936 17 Beta-amino and hydroxylamino-11 beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 02/05/2004 | US20040023932 Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the |
| 02/05/2004 | US20040023931 Method for maintaining a healthy bone structure by administering to a patient a bone health promoting effective amount of a medicament containing 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic |
| 02/05/2004 | US20040023925 Method for enhancing the effectiveness of therapies of hyperproliferative diseases |
| 02/05/2004 | US20040023885 Islet neogenesis therapy comprising an EGF and a gastrin in combination with immune suppression, and for treating or preventing early stage diabetes with a gastrin/CCK receptor ligand and an immunosuppressant are provided |
| 02/05/2004 | US20040023883 IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively. |
| 02/05/2004 | US20040023879 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 02/05/2004 | US20040023877 Plasminogen fragments containing kringle region domains having anti-angiogenic activity and terned angiostatin protein. The plasminogen fragments of the present invention may be used for the treatment of angiogenesis-dependent diseases such as |
| 02/05/2004 | US20040023872 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage |
| 02/05/2004 | US20040023859 New melanocortin receptor ligands are cyclic peptide analogs that preferably exhibit selectivity for the MC-4 and/or the MC-3 receptors relative to the other melanocortin receptors |
| 02/05/2004 | US20040023858 Antifungal combination therapy |
| 02/05/2004 | US20040023854 Adiponectin and uses thereof |
| 02/05/2004 | US20040023851 Method for the porduction of artificial oxygen carriers from covalently cross linking haemoglobin with improved functional properties of haemoglobin by cross- linking in the presence of chemically non- reacting effectors of the oxygen affinity of the haemoglobin |
| 02/05/2004 | US20040023843 Treatment of an emotional disorder, which contains the NK-1 receptor antagonist having particular properties of (1) having no serotonin uptake inhibitory effect, (2) being capable of migrating into the hypothalamus, or (3) having an |
| 02/05/2004 | US20040023840 Combination of organic compounds |
| 02/05/2004 | US20040023392 Use in introducing predetermined change at predetermined location in target gene in living cell; oligodeoxynucleotide is modified by attachment of 3' and 5' blocking substituents such as a 3'-3'linked cytosine nucleotide and a 5' linked dye |
| 02/05/2004 | US20040023340 Method for producing human anti-thymocyte immunoglobulins |
| 02/05/2004 | US20040023335 IL-17 like molecules and uses thereof |
| 02/05/2004 | US20040023313 Comprises monoclonal antibody which specifically binds osteoprotegerin ligand (OPGL) for diagnosis, prevention and treatment of bone disorders |
| 02/05/2004 | US20040023290 Novel therapeutic agents that modulate enzymatic processes |
| 02/05/2004 | US20040023240 Combinatorial production of nucleotide and nucleoside(xitp)analogues |
| 02/05/2004 | US20040023204 Peptides which enhance transport across tissues and methods of identifying and using the same |
| 02/05/2004 | US20040022879 Platelet Activating Factor Inhibitor and an antioxidant which interferes with the arachidonic acid cascade and also has antioxidant activity; especially useful for treating asthma in children. |
| 02/05/2004 | US20040022871 Halogenated composition, method for preparing same and uses thereof |
| 02/05/2004 | US20040022854 Oral administration of proton pump inhibitor |
| 02/05/2004 | US20040022831 For therapy of mycosis of the nail |
| 02/05/2004 | US20040022791 Use of the heavy chain of an antibody, of a functional derivative, or of a fragment thereof, comprising a CDR3 region for jointly inhibiting fibrinogen binding to platelets and vitronectin binding to endothelial cells |
| 02/05/2004 | US20040022785 Expression of herstatin, an alternative HER-2/neu product, in cells that express either p185HER-2 or the EGF receptor inhibits receptor activity and cell growth |
| 02/05/2004 | US20040022778 For therapy and prophylaxis of cardiovascular disease, strokes and myocardial infarction |
| 02/05/2004 | US20040022762 Use of il-8 protein modulators in the treatment of viral infections |
| 02/05/2004 | US20040022727 For therapy of proliferative diseases |
| 02/05/2004 | CA2727782A1 Canine respiratory coronavirus (crcv) spike protein, polymerase and hemagglutinin/esterase |
| 02/05/2004 | CA2494668A1 Chemical compounds |
| 02/05/2004 | CA2494358A1 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 02/05/2004 | CA2494262A1 Polymorphisms for predicting disease and treatment outcome |
| 02/05/2004 | CA2494069A1 Pellicle-resistant gelatin capsule |
| 02/05/2004 | CA2493980A1 Gelatin capsule exhibiting reduced cross-linking |
| 02/05/2004 | CA2493790A1 Food improving blood flow |
| 02/05/2004 | CA2493761A1 Compositions comprising hmg-coa reductase inhibitor |
| 02/05/2004 | CA2493751A1 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 02/05/2004 | CA2493639A1 Persulfated oligosaccharide acting on selectins and chemokine |
| 02/05/2004 | CA2493629A1 Pramipexole once-daily dosage form |
| 02/05/2004 | CA2493179A1 Sustained-release tablet composition comprising a dopamine receptor agonist |
| 02/05/2004 | CA2493156A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 02/05/2004 | CA2493078A1 Medicament dispenser |
| 02/05/2004 | CA2493076A1 Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
| 02/05/2004 | CA2493074A1 Use of a rhein in a therapeutic treatment requiring a rise in the rate of heme oxygenase |
| 02/05/2004 | CA2492858A1 Use of digoxin immune fab for the regulation of sodium/potassium atpase activity in preeclamptic and eclamptic patients |
| 02/05/2004 | CA2492542A1 Oligodendrocyte production from multipotent neural stem cells |
| 02/05/2004 | CA2492447A1 Taci antibodies and uses thereof |
| 02/05/2004 | CA2492444A1 Modified adamts4 molecules and method of use thereof |
| 02/05/2004 | CA2492333A1 Canine respiratory coronavirus (crcv) spike protein, polymerase and hemagglutinin/esterase |
| 02/05/2004 | CA2492210A1 Aryl substituted hydantoin compounds and their use as sodium channel blockers |
| 02/04/2004 | EP1386923A1 Novel adenine derivatives |
| 02/04/2004 | EP1386920A1 Benzimidazolone derivatives |
| 02/04/2004 | EP1386919A1 Remedies |
| 02/04/2004 | EP1386912A1 Cyclic amidine derivative |
| 02/04/2004 | EP1386908A1 Amine derivative with potassium channel regulatory function, its preparation and use |
| 02/04/2004 | EP1386905A1 Stable solution of reduced coenzyme q |
| 02/04/2004 | EP1386615A1 EG-VEGF/Prokineticin 2 receptor antagonists |
| 02/04/2004 | EP1386612A1 Drugs fo rpromoting the proliferation, differentiation and/or survival of glial cells containing cyclic phosphatidic acid |
| 02/04/2004 | EP1386611A1 Medicines and medicinal kits |
| 02/04/2004 | EP1386610A1 Medicament containing 2-HETE or 11,12-EET |
| 02/04/2004 | EP1386605A1 Improved transdermal delivery system for the administration of rotigotine |
| 02/04/2004 | EP1386604A1 Improved transdermal delivery system |
| 02/04/2004 | EP1386279A2 Method for inhibiting metap2 |
| 02/04/2004 | EP1386166A2 Anti-epileptogenic agents |
| 02/04/2004 | EP1386155A2 Therapeutic and diagnostic uses of antibody specificity profiles |
| 02/04/2004 | EP1385981A2 Antifungal compounds and methods of use |
| 02/04/2004 | EP1385977A2 Secreted proteins |
| 02/04/2004 | EP1385966A2 Recombinant fusion proteins and the trimers thereof |
| 02/04/2004 | EP1385955A2 Cell adhesion proteins |
| 02/04/2004 | EP1385954A2 Proteins associated with cell growth, differentiation, and death |
| 02/04/2004 | EP1385953A2 Proteins and nucleic acids encoding same |
| 02/04/2004 | EP1385937A1 Delivery of polynucleotide agents to the central nervous sysstem |
| 02/04/2004 | EP1385934A2 Pufa polyketide synthase systems and uses thereof |
| 02/04/2004 | EP1385874A1 Alpha conotoxin peptides with analgesic properties |